乳腺癌扩张器金属端口术后调强质子治疗初步临床经验
结果显示靶区覆盖与正常组织剂量不确定性小且临床可接受,急性放射性皮炎以1-2级为主,仅1例3级。结论认为该治疗可行,但各机构需自行分析所用扩张器的物理特性。
要点
- 扩张器金属端口对IMPT靶区覆盖和正常组织剂量的不确定性小且临床可接受。
- 急性放射性皮炎最高为3级1例,2级5例,1级6例。
- 各机构在开展IMPT前应分析所用扩张器的物理特性及剂量学影响。
核心结论
- 乳腺癌扩张器患者术后IMPT可行,靶区覆盖和正常组织保护良好,即使考虑治疗不确定性。
主要发现
- 9例双侧保留皮肤乳房切除+双侧扩张器重建,3例单侧;左侧治疗10例,右侧2例。
- 扩张器导致的靶区覆盖和正常组织剂量不确定性小且临床可接受。
- 急性放射性皮炎最高3级1例,2级5例,1级6例。
关键数值与推荐
- 质子射程通过样本植入物验证,计划剂量学用基于GPU的蒙特卡洛模拟核查。
临床怎么用
- 考虑对使用扩张器的乳腺癌患者开展IMPT,但需先分析本机构所用扩张器的物理特性和剂量学影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The feasibility of proton postmastectomy radiation therapy in patients reconstructed with expanders has not been previously reported, limiting treatment options. We analyzed the dosimetric impact of the metallic port contained within expanders on intensity modulated proton therapy (IMPT) and report our techniques and quality control for treating patients in this setting. METHODS AND MATERIALS: Twelve patients with the same expander model underwent 2-field IMPT as part of a prospective registry. All planning dosimetry was checked with an in-house graphic processing unit--based Monte Carlo simulation. Proton ranges through the expander were validated using a sample implant. Dosimetric impact of setup metallic port position uncertainty was evaluated. Pre- and posttreatment photographs were obtained and acute toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: Nine patients had bilateral skin-sparing mastectomy with bilateral tissue expander reconstruction, and 3 patients had unilateral skin-sparing mastectomy and reconstruction. The left side was treated in 10 patients and the right side in 2. Target coverage and normal tissue dose uncertainties resulting from the expander were small and clinically acceptable. The maximum physician-assessed acute radiation dermatitis was grade 3 in 1 patient, grade 2 in 5 patients, and grade 1 in 6 patients. CONCLUSIONS: Postmastectomy IMPT in breast cancer patients with expanders is feasible and associated with favorable clinical target volume coverage and normal tissue sparing, even when taking into account treatment uncertainties; therefore, these patients should be eligible to participate in clinical trials studying the potential role of proton therapy in breast cancer. We caution, however, that institutions should carry out similar analyses of the physical properties and dosimetric impact of the particular expanders used in their practice before considering IMPT.
引用
- Mutter RW, Remmes NB, Kahila MM, et al. Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports. Pract Radiat Oncol. 2016. PMID: 28341315. doi:10.1016/j.prro.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。